Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management (PROSPER-FM)
"PROSPER-FM": Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Nicolette Vega
- Phone Number: 415-322-0467
- Email: prosperfmstudy@swingtherapeutics.com
Study Locations
-
-
California
-
Covina, California, United States, 91722
- Site #37
-
Oceanside, California, United States, 92056
- Site #15
-
San Bernardino, California, United States, 92498
- Site #31
-
Thousand Oaks, California, United States, 91360
- Site #38
-
Tujunga, California, United States, 91042
- Site #36
-
Whittier, California, United States, 90602
- Site #35
-
-
Florida
-
Orlando, Florida, United States, 32801
- Site #13
-
Saint Petersburg, Florida, United States, 33709
- Site #33
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Site #25
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Site #21
-
New Orleans, Louisiana, United States, 70124
- Site #20
-
Prairieville, Louisiana, United States, 70769
- Site #22
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 02467
- Site #39
-
-
Mississippi
-
Ocean Springs, Mississippi, United States, 39564
- Site #24
-
-
New York
-
Brooklyn, New York, United States, 11235
- Site #34
-
Scarsdale, New York, United States, 10583
- Site #32
-
Williamsville, New York, United States, 14221
- Site #12
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Site #27
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Site #14
-
Dayton, Ohio, United States, 45419
- Site #28
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74133
- Site #23
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Site #16
-
-
Texas
-
Austin, Texas, United States, 78726
- Site #29
-
McKinney, Texas, United States, 75070
- Site #26
-
Pflugerville, Texas, United States, 78660
- Site #30
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participant is 22 to 75 years of age, inclusive
- Participant has a diagnosis of primary FM as defined by the 2016 American College of Rheumatology Preliminary Diagnostic Criteria for FM
- Participants with ongoing treatments should be on stable therapy for 30 days prior to screening appointment.
- Participant is capable of reading and understanding English and has provided written informed consent to participate.
Key Exclusion Criteria:
- Lifetime history of bipolar or other psychotic disorder
- Severe depression at screening (measured by BDI-II)
- The participant is at increased risk of suicide on the basis of the investigator's judgment or the Columbia-Suicide Severity Rating Scale ("C-SSRS")
- Participant has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the participant, interfere with the evaluation of the study device's efficacy or safety, or compromise the participant's ability to comply with/complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Digital Acceptance and Commitment Therapy (ACT) Arm
|
Participants in this arm receive Digital ACT as well as standard of care.
|
|
Active Comparator: Digital Symptom Tracker
|
Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Patient Global Impression of Change (PGIC) response rate
Time Frame: Week 12
|
Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lesley Arnold, MD, study principal investigator
- Study Chair: Michael Gendreau, MD, Consulting Chief Medical Officer
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Swing-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.